statistiche ricercatore

Continente	#
NA - Nord America	1.139
EU - Europa	844
AS - Asia	632
SA - Sud America	69
AF - Africa	27
OC - Oceania	2
Continente sconosciuto - Info sul continente non disponibili	1
Totale	2.714

Nazione	#
US - Stati Uniti d'America	1.115
GB - Regno Unito	237
CN - Cina	201
SG - Singapore	157
DE - Germania	151
IT - Italia	138
SE - Svezia	72
HK - Hong Kong	59
BR - Brasile	48
RU - Federazione Russa	48
IN - India	46
UA - Ucraina	41
BD - Bangladesh	39
NL - Olanda	37
FR - Francia	35
KR - Corea	34
VN - Vietnam	30
TR - Turchia	20
CA - Canada	19
EU - Europa	19
IE - Irlanda	17
PL - Polonia	17
CI - Costa d'Avorio	16
BE - Belgio	15
FI - Finlandia	15
JP - Giappone	13
CO - Colombia	12
GR - Grecia	9
ID - Indonesia	8
AR - Argentina	3
DK - Danimarca	3
KZ - Kazakistan	3
PK - Pakistan	3
AU - Australia	2
CL - Cile	2
CZ - Repubblica Ceca	2
IL - Israele	2
IQ - Iraq	2
IR - Iran	2
KE - Kenya	2
MX - Messico	2
NG - Nigeria	2
PH - Filippine	2
TH - Thailandia	2
ZA - Sudafrica	2
AE - Emirati Arabi Uniti	1
AL - Albania	1
AO - Angola	1
AT - Austria	1
AZ - Azerbaigian	1
CG - Congo	1
CR - Costa Rica	1
DZ - Algeria	1
EC - Ecuador	1
EE - Estonia	1
ES - Italia	1
HU - Ungheria	1
JM - Giamaica	1
JO - Giordania	1
KG - Kirghizistan	1
LB - Libano	1
MU - Mauritius	1
MY - Malesia	1
NP - Nepal	1
OM - Oman	1
PA - Panama	1
PE - Perù	1
PY - Paraguay	1
RO - Romania	1
SK - Slovacchia (Repubblica Slovacca)	1
SN - Senegal	1
TW - Taiwan	1
VE - Venezuela	1
Totale	2.732

Nome	#
Efficacy and tolerability of multiple drug therapy in HIV-infected children	392
Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir	333
Accumulation of drug-related mutations in HIV-1 genome and virus replicative capacity in multi-drug failure subjects	300
In vitro efficacy of a non-conventional (folding) HIV-1 protease inhibitor without selection of resistance	297
Analysis of protease inhibitor combinations in vitro : activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates	284
New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses	268
Susceptibility to a non-conventional (folding) protease inhibitor of human immunodeficiency virus type 1 isolates in vitro	257
Absence of new thymidine-associated mutations and evidence of an immune virologic response over a 12-month period in a cohort of antiretroviral- experienced HIV-1-infected subjects treated with tenofovir combination therapy [2]	238
The non-conventional (folding) protease inhibitor blocks the human immunodeficiency virus type-1 replication without evidence of resistance during in vitro passage	236
Susceptibility to a non-conventional (folding) protease inhibitor of human immunodeficiency virus type 1 isolates in vitro	209
Totale	2.814

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	52	0	0	0	0	0	0	0	0	0	0	47	5
2021/2022	160	19	9	10	10	9	8	14	18	18	15	5	25
2022/2023	220	20	29	17	31	19	39	18	16	23	0	6	2
2023/2024	102	3	8	5	9	21	14	11	5	0	2	8	16
2024/2025	339	14	39	6	45	18	20	19	28	18	38	23	71
2025/2026	686	65	58	80	54	53	40	65	24	58	78	111	0
Totale													2.814

IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca